Search

Displaying results 3911 - 3920 of 10000 in total
  1. Drug

    LS11

    go.drugbank.com/drugs/DB05918
    Investigational

    LS11(talaporfin sodium) is an agent consisting of chlorin e6, derived from chlorophyll, and L-aspartic acid with photosensitizing activity. … It is used to treat many kinds of cancers.

  2. Drug

    MEM 1414

    go.drugbank.com/drugs/DB05888
    Experimental

    MEM 1414 is a PDE4 inhibitor that is being evaluated for the treatment of Alzheimer’s disease. This drug candidate has completed Phase 1 clinical trials.

  3. Drug

    Sodium copper chlorophyllin

    go.drugbank.com/drugs/DB16522
    Investigational

    This compound is used as a food colorant and supplement[A227718]. … SCC of the commercial-grade is prepared from a reaction between a crude chlorophyll extract and methanolic sodium hydroxide, followed by replacement of the central magnesium atom with a heavy metal[A227718

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds with 4 or More Rings
  4. Drug

    DP-VPA

    go.drugbank.com/drugs/DB05821
    Investigational

    DP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure

  5. Drug

    Cixutumumab

    go.drugbank.com/drugs/DB12250
    Investigational

    Cixutumumab is a highly specific recombinant human monoclonal antibody with high affinity for the insulin-like growth factor-I receptor (IGF-IR). IGF-IR is overexpressed in a variety of tumour types.

    Categories: Receptor, IGF Type 1
  6. Drug

    Canertinib

    go.drugbank.com/drugs/DB05424
    Investigational

    Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo.

    Categories: Heterocyclic Compounds, 1-Ring, Compounds used in a research, industrial, or household setting
  7. Drug

    AX200

    go.drugbank.com/drugs/DB05093
    Investigational

    AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. … And this is where the double neurotherapeutic approach is most beneficial: AX200 stops neuronal cell death in the acute phase of stroke, while stimulating simultaneously the regeneration of nervous tissue

  8. Drug

    Veglin

    go.drugbank.com/drugs/DB05890
    Experimental

    VEGF-AS (Veglin) is an anti-angiogenesis non-chemotherapy drug (angiogenesis inhibitor) that was developed by VasGene Therapeutics, Inc. for the treatment of a variety of malignancies including mesothelioma … Veglin is one of several newly developed non-chemotherapy drugs being tested for possible utilization in the ongoing struggle to combat malignant mesothelioma.

  9. Drug

    Altropane

    go.drugbank.com/drugs/DB04947
    Investigational

    Boston Life Sciences (BLS) is developing Altropane as a potential radio-imaging agent to be used with single photon emission tomography (SPECT), for the early diagnosis of Parkinson's disease (PD) and

  10. Drug

    LI-301

    go.drugbank.com/drugs/DB05509
    Experimental

    LI 301 is an orally bio-available compound delivered in a fast melt mechanism with taste masking enabling it to be taken anytime without water. … It has a novel mode of action combining both the light effect of a Selective Serotonin Reuptake Inhibitor ("SSRI")(most likely antagonistic at 5HT1a receptors) and antagonism at mu-opioid receptors.